NCT07154706 2026-02-11Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)Nuvation Bio Inc.Phase 3 Recruiting180 enrolled
NCT06214793 2025-05-01Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)Case Comprehensive Cancer CenterPhase 2 Suspended61 enrolled